Tetraphase Pharmaceuticals Announces Pricing of Initial Public Offering
WATERTOWN, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of
its initial public offering of 10,714,286 shares of common stock at a
price to the public of $7.00 per share, less underwriting discounts and
commissions. Tetraphase's common stock is expected to begin trading on
the NASDAQ Global Market under the symbol "TTPH" on March 20, 2013.
Tetraphase has granted the underwriters a 30-day option to purchase up
to 1,607,143 additional shares of common stock at the same price to
cover over allotments, if any.
Barclays and BMO Capital Markets are acting as joint book-running
managers. Stifel, JMP Securities and Needham & Company are acting as
co-managers for the offering. A registration statement relating to these
securities has been declared effective by the Securities and Exchange
Commission (SEC). The offering is being made only by means of a
prospectus. A copy of the final prospectus relating to these securities
will be filed with the SEC and may be obtained, when available, from:
Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847, or
by emailing email@example.com,
or by calling BMO Capital Markets at (800) 414-3627, or by emailing firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for serious
and life-threatening multi-drug resistant infections. Tetraphase's lead
product candidate, eravacycline, is a fully synthetic tetracycline
derivative being developed as a broad-spectrum intravenous and oral
antibiotic for use as a first-line empiric monotherapy for the treatment
of multi-drug resistant infections, including multi-drug resistant
Senior Vice President
Sam Brown Inc.
Source: Tetraphase Pharmaceuticals
News Provided by Acquire Media
Close window | Back to top